Would IgG be high or low 2 weeks after EBV (Epstein-Barr Virus) clinical symptoms onset?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 27, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

After 2 weeks of clinical symptoms of Epstein-Barr virus (EBV) infection, IgG antibodies would typically be low or still rising, as the immune system takes time to switch from producing IgM to IgG antibodies. The immune response to EBV infection involves an initial increase in IgM antibodies, which can be detected early in the infection, followed by a switch to IgG production as the infection progresses 1. According to the guidelines by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM), heterophile antibodies, which are a type of IgM antibody, usually become detectable between the sixth and tenth day following symptom onset and increase through the second or third week of the illness 1. The presence of VCA IgM (with or without VCA IgG) antibodies in the absence of antibodies to EBNA indicates recent primary infection with EBV, and it is not until later, typically more than 6 weeks after symptom onset, that EBNA antibodies, which are IgG, become detectable 1. Therefore, at 2 weeks after symptom onset, the IgG response may still be in its early stages, and IgG levels may not have reached their peak. Key points to consider in the diagnosis of EBV infection include:

  • The timing of symptom onset and the type of antibodies present
  • The distinction between acute and past infections based on IgM and IgG levels
  • The use of additional laboratory tests, such as EBV antibody testing for IgG and IgM to viral capsid antigen (VCA) and Epstein-Barr nuclear antigen (EBNA), to confirm the diagnosis 1.

From the Research

EBV Infection and IgG Levels

  • Epstein-Barr virus (EBV) has a long incubation period, typically lasting around six weeks 2.
  • During this incubation period, the virus replicates in the oral cavity and disseminates to the blood, where it can be detected at low levels about 3 weeks before symptoms appear 3.
  • The immune response to EBV infection involves the expansion of natural killer cells and the decrease of plasmacytoid dendritic cells, but these changes occur after symptom onset 3.
  • The measurement of EBV-IgG anti-VCA avidity can aid in the early and reliable diagnosis of primary EBV infection, as low-avidity IgG anti-VCA is indicative of recent infection 4.

IgG Levels After 2 Weeks of Clinical Symptoms

  • After 2 weeks of clinical symptoms, IgG levels are likely to be high, as the immune response to EBV infection is characterized by the production of IgG antibodies against the viral capsid antigen (VCA) and Epstein-Barr nuclear antigen (EBNA-1) 4.
  • The avidity of IgG anti-VCA antibodies, which measures the strength of binding between the antibody and the antigen, increases over time after infection, with mean avidity rising from 54% at 6 weeks to 82% by 28 weeks after the onset of symptoms 4.
  • Therefore, after 2 weeks of clinical symptoms, IgG levels are expected to be high, but the avidity of IgG anti-VCA antibodies may still be relatively low, indicating recent infection 4.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Primary Epstein-Barr virus infection.

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2018

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.